Vincenzo Fiorentini

Vincenzo Fiorentini

Auto-generated profile, based on publicly available information

Vincenzo Fiorentini

Cardiology Unit, Sant'Andrea University Hospital, 00189 Rome, Italy

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2024 in Reviews in Cardiovascular Medicine
Verified
Journal Article
Open access
PDF file
ATAntonella Tommasino
Antonella Tommasino
VFVincenzo Fiorentini
Vincenzo Fiorentini
GMGiulia Mattaroccia
Giulia Mattaroccia
ASAlessandra Scoccia
Alessandra Scoccia
EBEmanuele Barbato
Emanuele Barbato
The P2Y12 receptor plays a central role in platelet activation, secretion, and procoagulant activity. The CURE (clopidogrel in unstable angina to prevent recurrent events) trial, conducted in 2001, was the first to effectively demonstrate the benefit of dual anti-aggregation therapy with aspirin and clopidogrel in patients with acute coronary syndromes (ACS) undergoing invasive treatment. Since then, the field of interventional cardiology has changed considerably. The introduction of drug-eluting stents (DES) and the development of new, potent P2Y12 inhibitors such as ticagrelor, prasugrel and cangrelor have revolutionized the treatment of ACS. Nevertheless, ST-elevation myocardial infarction (STEMI) remains a critical condition that requires rapid and effective intervention. The use of P2Y12 receptor antagonists as part of the pretreatment strategy is an interesting topic to optimize outcomes in STEMI patients. This review summarizes the existing evidence on the efficacy and safety of pretreatment with P2Y12 receptor antagonists in STEMI, and emphasizes the importance of making pretreatment decisions based on individual clinical characteristics. The review also looks to the future, pointing to the potential role of artificial intelligence (AI) in improving STEMI diagnosis and treatment decisions, suggesting a future where technology could improve the accuracy and timeliness of care for STEMI patients.

6 June 2024 in The Heart Surgery Forum
Verified
Journal Article
Closed access
PDF file
ATAntonella Tommasino
Antonella Tommasino
ENEmiliano Marco Navarra
Emiliano Marco Navarra
FDFederico Dell'Aquila
Federico Dell'Aquila
CCCamilla Ciani
Camilla Ciani
VFVincenzo Fiorentini
Vincenzo Fiorentini
GMGiovanni Melina
Giovanni Melina
The treatment of coronary artery disease (CAD) has considerably evolved over the last three decades thanks to innovations in percutaneous and surgical revascularization techniques. The demographic shift towards an aging population with complex coronary anatomy and multiple comorbidities necessitates a personalized approach. A primary challenge for Heart Teams is to integrate new strategies into their decision-making process. Hybrid coronary revascularization (HCR) combines the long-term benefits of coronary artery bypass grafting (CABG) with percutaneous coronary intervention (PCI) to treat complex coronary artery disease. Selection of the ideal candidate for HCR requires careful evaluation of anatomic challenges and risk profiles. Although recent evidence demonstrates the safety and efficacy of HCR and makes it a viable alternative to conventional methods, further large-scale randomized controlled trials (RCTs) are needed to establish its role in routine practice. In this manuscript, we have provided an overview of the major advances in both percutaneous and surgical techniques. In addition, we have addressed the innovative implications of robotic-assisted minimally invasive direct coronary artery bypass (RA-MIDCAB) and described the surgical procedure and postoperative care in detail. Finally, we have outlined the key principles that guide our clinical practice in selecting the appropriate approach for hybrid coronary revascularization.